AstraZeneca Holds Preliminary Talks with Bristol Myers Squibb on Potential $400 Billion Merger
oncodaily - A deal that could create the world’s fourth-largest drugmaker British pharmaceutical leader AstraZeneca has held confidential, preliminary discussions regarding a potential combination with US rival Bristol Myers Squibb(BMS). A completed […]
AI Summary: AstraZeneca entered preliminary, non-binding talks with Bristol Myers Squibb about a potential $400 billion merger, probing whether combining pipelines and scale could reshape oncology and other businesses. The discussions are early, sparking market speculation and likely regulatory scrutiny as executives weigh strategic synergies against integration complexity and antitrust risk.
Senate Moves to Keep Politics Out of Cancer Research Funding
oncodaily - On August 2, 2026, US senators introduced a bipartisan temporary spending bill aimed at keeping the federal government funded. The bill also included a provision that would pause earlier proposed […]
AI Summary: Lawmakers advanced a bipartisan measure designed to delay a controversial OMB grantmaking rule and protect peer‑reviewed cancer research funding from politicized oversight. Scientific groups welcomed the move as a pragmatic step to preserve grant integrity and ensure researchers can continue work without sudden administrative disruptions.
- Clinical leaders defend peer review, oppose politicized funding (3)
- Inclusion and funding roles shaping cancer clinical research (3)
- Senate stalls OMB rule to shield cancer grants (3)
Clinical leaders defend peer review, oppose politicized funding
Inclusion and funding roles shaping cancer clinical research
Senate stalls OMB rule to shield cancer grants
FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
oncodaily - On July 31, 2026, the US Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults […]
AI Summary: The FDA has approved an expanded use for a lutetium‑177 radiopharmaceutical (Pluvicto), broadening access for PSMA‑positive metastatic prostate cancer patients and potentially speeding the adoption of targeted radionuclide therapy. Clinicians note the approval could shift treatment sequencing and patient pathways, with implementation details and eligibility criteria guiding real‑world impact.
- Access, dose optimization and real-world data for Lu-177 (4)
- FDA expands Pluvicto approval; industry reaction (3)
- PSMAddition trial: earlier Lu-177 delays metastatic progression (5)
Access, dose optimization and real-world data for Lu-177
FDA expands Pluvicto approval; industry reaction
PSMAddition trial: earlier Lu-177 delays metastatic progression
Mel Mann Highlights First Patient Enrollment in AACR-ADOPT-GEA Trial
oncodaily - Mel Mann, World’s Longest Living Gleevec (Imatinib) / TKI Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared American Association for Cancer Research (AACR) […]
AI Summary: The AACR‑affiliated ADOPT‑GEA phase II trial for locally advanced gastroesophageal cancer has reported its first patient enrollment, marking a key milestone in the study's launch. The enrollment signals trial readiness and opens recruitment momentum to evaluate investigational approaches for a challenging cancer subtype, advancing potential new treatment options toward evidence‑based use.
NCCS Develops AI Tool to Predict Liver Cancer Recurrence After Surgery
oncodaily - National Cancer Centre Singapore (NCCS) shared on LinkedIn: “Can we now predict who’s at greatest risk for liver cancer recurrence? Congratulations to NCCS’ Professor Pierce Chow, Associate Professor Wai Leong Tam, Mr. Karthik Sekar, […]
AI Summary: A newly developed AI model predicts risk of liver cancer recurrence following surgical resection, integrating imaging and clinical variables to stratify patients more accurately. Early validation suggests the tool could personalize surveillance intensity and adjuvant therapy decisions, reducing unnecessary exams for low‑risk patients while focusing resources where recurrence risk is highest.
International project delivers hundreds of next-generation models for cancer research
medicalxpress - Ten years and thousands of patient samples later, the National Cancer Institute (NCI) has published its results from the Human Cancer Model Initiative (HCMI) on the development of 665 organoid models of 25 types of cancer that are now available to scienti…
AI Summary: An international consortium released hundreds of patient‑derived tumor models, including a public HCMI set of 665 organoids, creating a living biobank for drug discovery. Labs worldwide now gain access to diverse, next‑generation models to test therapies and probe cancer vulnerabilities — a major boost for preclinical translational work.
- Experts react: three Nature papers and model summaries (3)
- HCMI release: 665 organoids unveiled in Nature (4)
- Organoids power maps and predictors of therapy resistance (4)